Friend MTS, Leading Global Provider of Content Protection Services, Announces Appointment of Derek Chang to Chief Executive Officer
2.6.2021 14:00:00 EEST | Business Wire | Press release
Friend MTS is pleased to announce the appointment of Derek Chang to Chief Executive Officer (CEO). A seasoned industry executive with a career spanning three decades, Chang previously served as CEO of NBA China, and has held leadership positions with several recognized sports, media and entertainment providers. He will be based in London.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005316/en/
Derek Chang, Chief Executive Officer, Friend MTS (Photo: Business Wire)
“It is my privilege to join Friend MTS as we ramp up our innovation of the technology essential to protect the needs of a complex global media industry,” said Chang. “We are at the forefront of rapid changes in consumer behavior, new business models and technology, and will ensure that creators, owners and distributors worldwide will have the formidable tools necessary to protect their valuable content.”
The announcement was made today by Jonathan Friend, Founder, Friend MTS, who previously served as CEO. A visionary in the field of content protection technologies, Friend will serve as Chief Product Officer (CPO) and continue to drive growth through the creation of the company’s advanced proprietary solutions.
“As we continue to innovate with groundbreaking solutions that our valued customers and partners have come to expect, now is the time to transition to our next leader and we are thrilled to welcome Derek to the helm of Friend MTS,” said Friend. “With deep expertise in the global sports and entertainment space, Derek brings invaluable insight to leveraging technology to create an impactful footprint for an ever-evolving media and content ecosystem.”
Prior to leading NBA China’s business, Chang was Head of International Lifestyle Channels for Scripps Networks Interactive, and had served as Executive Vice President, Content, DIRECTV. He also held senior roles for Charter Communications, the YES Network and TCI Communications. Chang currently serves on the board of directors for Liberty Media Corp. and Isos Acquisition Corp., and formerly served on the board of Starz.
Chang was named one of the “50 Most Influential People in Sports Business” by Sports Business Journal, as well as Cablefax Magazine's “Top 100 Executives in Cable.” He holds an MBA from Stanford University and a bachelor's degree in history from Yale University. He is a member of the Committee of 100 and serves on the advisory board of Row New York.
For press use, Friend MTS photo assets can be downloaded here. For more information, please visit www.friendmts.com or follow on LinkedIn and Twitter.
About Friend MTS:
Friend MTS is a leading global provider of innovative content protection technology solutions developed to advance a complex and ever-evolving media industry in collaboration with content owners, broadcasters and operators. With a comprehensive suite of advanced proprietary services ranging from content monitoring, fingerprinting and watermarking to enforcement and IP blocking, Friend MTS provides an end-to-end approach to disrupt real-world piracy and safeguard a worldwide entertainment and media market into the future. Playing an important role in social responsibility, Friend MTS has gifted organizations like the U.S. Department of Homeland Security and the International Center for Missing and Exploited Children (ICMEC) with its award-winning technology to help combat online child abuse. Founded in 2000, Friend MTS is privately held and headquartered in Birmingham, U.K. and Philadelphia, Pennsylvania, with operations throughout Europe, Asia, the Middle East, Africa, Latin America and North America.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005316/en/
Contact information
Friend MTS Media Contact:
Nora Ellish
+1 (917) 744-9200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
